Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
Orchestra BioMed Holdings, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$5.61 |
52 Week High | US$11.69 |
52 Week Low | US$4.22 |
Beta | 0.43 |
11 Month Change | -9.37% |
3 Month Change | -29.79% |
1 Year Change | -9.37% |
33 Year Change | -42.73% |
5 Year Change | n/a |
Change since IPO | -50.79% |
Recent News & Updates
Shareholder Returns
OBIO | US Medical Equipment | US Market | |
---|---|---|---|
7D | -16.3% | -1.4% | -4.4% |
1Y | -9.4% | 14.0% | 19.1% |
Return vs Industry: OBIO underperformed the US Medical Equipment industry which returned 14% over the past year.
Return vs Market: OBIO underperformed the US Market which returned 19.1% over the past year.
Price Volatility
OBIO volatility | |
---|---|
OBIO Average Weekly Movement | 13.2% |
Medical Equipment Industry Average Movement | 8.6% |
Market Average Movement | 6.3% |
10% most volatile stocks in US Market | 14.9% |
10% least volatile stocks in US Market | 3.1% |
Stable Share Price: OBIO's share price has been volatile over the past 3 months.
Volatility Over Time: OBIO's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
n/a | 56 | David Hochman | orchestrabiomed.com |
Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company’s flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension (HTN); and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold devices and minimally invasive surgery devices.
Orchestra BioMed Holdings, Inc. Fundamentals Summary
OBIO fundamental statistics | |
---|---|
Market cap | US$212.20m |
Earnings (TTM) | -US$55.58m |
Revenue (TTM) | US$2.08m |
102.1x
P/S Ratio-3.8x
P/E RatioIs OBIO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
OBIO income statement (TTM) | |
---|---|
Revenue | US$2.08m |
Cost of Revenue | US$166.00k |
Gross Profit | US$1.91m |
Other Expenses | US$57.49m |
Earnings | -US$55.58m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -1.47 |
Gross Margin | 92.02% |
Net Profit Margin | -2,673.26% |
Debt/Equity Ratio | 0% |
How did OBIO perform over the long term?
See historical performance and comparison